Page 1 of 1

Croatian article

PostPosted: August 3rd, 2005, 3:09 am
by Slavin Balen
Following article was printed in Croatian daily newspaper yesterday:
PLIVA divests CNS franchize from proprietary portfolio

PLIVA d.d. announced today that, following its decision in May 2005 to exit the proprietary business, it has entered into an agreement with Canada-based Legacy Pharma Limited Partnership for the sale of CNS franchize of Odyssy Pharmaceuticals Inc., PLIVA U.S. specialty branded pharmaceuticals subsidiary, consisting of Antabuse, Vivactil, Surmontil and PLD-180 (PLIVA's Phase I pipeline product candidate for the treatment of ALS).

BTW, Pliva is well known for SUMAMED (antibiotic) drug which is available in U.S.